| 摘要: |
| 目的：探讨益生菌辅助治疗儿童支气管哮喘伴变应性鼻炎（AR）的疗效及机制。方法：选取100例哮喘伴AR患儿，随机分为观察组和对照组各50例，对照组给予常规治疗，观察组在对照组基础上联合双歧杆菌乳杆菌三联活菌片治疗，连续治疗6个月。比较两组患儿哮喘控制测试（C-ACT）量表评分、第1秒时间肺活量（FEV1）、呼气峰值流速（PEF）、鼻部症状评分及血清干扰素-γ（IFN-γ）和白介素-4（IL-4）水平。结果：治疗后，观察组C-ACT评分、FEV1、PEF、鼻部症状评分、IFN-γ及IL-4分别为（24.6±2.3）分、（123.7±10.6）%、（125.2±8.3）L/min、（0.5±0.2）分、（43.6±4.8）g/L及（32.4±3.9）ng/L，对照组分别为（20.1±2.0）分、（108.4±14.3）%、（110.8±7.4）L/min、（0.9±0.3）分、（35.2±3.9）g/L及（44.8±4.7）ng/L，与对照组相比较，观察组C-ACT评分、FEV1、PEL、IFN-γ显著提高（P<0.05），同时鼻部症状评分及IL-4显著降低（P<0.05）。结论：益生菌辅助治疗哮喘伴AR可有效缓解临床症状，纠正Th1/Th2免疫失衡是其可能作用机制。 |
| 关键词: 支气管哮喘 变应性鼻炎 益生菌 Th1/Th2 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2016.12.009 |
|
| 基金项目: |
|
| The Efficacy and Mechanism of Probiotics in Children with Bronchial Asthma and Allergic Rhinitis |
| Han Bing1, Zhu Xiuping1, Sheng Huaiming1, Hong Qingrong2 |
| (1. Chinese Traditional and Western Medicine Hospital of Zhenjiang, Jiangsu ZhenJiang 21000, China; 2. The First People’s Hospital of Zhenjiang, Jiangsu ZhenJiang 21000, China) |
| Abstract: |
| Objective: To evaluate the efficacy and mechanism of probiotics in children with bronchial asthma and allergic rhinitis (AR). Methods: 100 children with bronchial asthma and AR were divided into observation group (n=50) and control group (n=50). The control group was treated with conventional therapy, and the observation group was treated with conventional therapy combined with live combined bifidobacterium and lactobacillus tablets, for 6 months. The childhood asthma control test (C-ACT) score, forced expiratory volume in 1s (FEV1), peak expiratory flow (PEF), nasal symptom scores, interferon-γ (IFN-γ) and interleukin-4 (IL-4) level were compared between the two groups. Results: The C-ACT, FEV1, PEF, nasal symptom scores, IFN-γ and IL-4 of observation group respectively was (24.6±2.3) scores, (123.7±10.6)%, (125.2±8.3) L/min, (0.5±0.2) scores, (43.6±4.8) g/L and (32.4±3.9) ng/L, those of control group respectively was (20.1±2.0) scores, (108.4±14.3)%, (110.8±7.4) L/min, (0.9±0.3) scores, (35.2±3.9) g/L and (44.8±4.7) ng/L. Compared with control group, the C-ACT, FEV1, PEL and IFN-γ of observation group significantly increased (P<0.05), and the nasal symptom scores and IL-4 of control group significantly decreased (P<0.05). Conclusion: Probiotics adjuvant therapy on bronchial asthma and AR, can effectively relieve the clinical symptoms, regulate Th1/Th2 immune imbalance may be its mechanism. |
| Key words: bronchial asthma allergic rhinitis probiotics Th1/Th2 |
